Tuberculosis (TB)

Multidrug-resistant tuberculosis (MDR-TB)

A neighbour provides water to a woman, India

Anti-tuberculosis (TB) drug resistance is a major public health problem that threatens progress made in TB care and control worldwide. Drug resistance arises due to improper use of antibiotics in chemotherapy of drug-susceptible TB patients. This improper use is a result of a number of actions including, administration of improper treatment regimens and failure to ensure that patients complete the whole course of treatment. Essentially, drug resistance arises in areas with weak TB control programmes. A patient who develops active disease with a drug-resistant TB strain can transmit this form of TB to other individuals.


Engaging all relevant health care providers in the management of DR-TB cases is an important intervention to achieve the goal of universal access to DR−TB care and services. However only limited progress has been made to date in engaging non-NTP providers in the management of DR-TB patients. Following in−country assessments to Myanmar, Nigeria, Pakistan and Turkey (from Nov 2013 to Feb 2014), an "Expert consultation meeting on public−private mix for the management of drug−resistant tuberculosis (PPM DR-TB)", was held in Geneva, Switzerland, 23 to 24 June 2014. The report of the meeting is now available. A WHO "Framework for PPM DR-TB" document is planned to be finalized by the end of 2014.